Personal information

Other IDs

SciProfiles: 2405623

Activities

Collapse all

Works (4)

Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Journal of Clinical Medicine
2024-06-21 | Journal article
DOI: 10.3390/jcm13133642
Contributors: Andrea Camerini; Francesca Mazzoni; Vieri Scotti; Carmelo Tibaldi; Andrea Sbrana; Luana Calabrò; Enrico Caliman; Lucia Pia Ciccone; Laura Bernardini; Jessica Graziani et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial

Cancers
2022-12-09 | Journal article
DOI: 10.3390/cancers14246074
Contributors: Andrea Camerini; Alessandro Del Conte; Aldo Pezzuto; Vieri Scotti; Francesco Facchinetti; Lucia Pia Ciccone; Marco Perna; Giulia Sartori; Cheti Puccetti; Alberto Ricci et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy

Advances in Therapy
2020-07-20 | Journal article
DOI: 10.1007/s12325-020-01386-y
Contributors: Maria Laura Canale; Andrea Camerini; Giancarlo Casolo; Alessio Lilli; Irma Bisceglia; Iris Parrini; Chiara Lestuzzi; Jacopo Del Meglio; Cheti Puccetti; Lara Camerini et al.
Source: check_circle
Crossref

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis

Clinical and Translational Oncology
2019-06 | Journal article
DOI: 10.1007/s12094-018-1989-y
Contributors: A. Camerini; G. L. Banna; S. Cinieri; A. Pezzuto; M. Mencoboni; F. Rosetti; A. Figueiredo; P. Rizzo; A. Ricci; L. Langenhoven et al.
Source: check_circle
Crossref

Peer review (20 reviews for 7 publications/grants)

Review activity for Advances in therapy. (11)
Review activity for BMC cancer (1)
Review activity for Breast cancer research and treatment. (1)
Review activity for Drugs - real world outcomes. (1)
Review activity for Lung cancer. (1)
Review activity for Oncology and therapy. (3)
Review activity for The Lancet regional health. (2)
How many people are using ORCID?